Loading
A phase 1/2 trial of Blinatumomab in acute lymphoblastic leukaemia, run by Amgen, active and no longer recruiting.
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia is a phase 1/2 interventional study registered as NCT07134088 by Amgen, with 104 participants enrolled, started 2025-12-08 and due to reach its primary completion in 2028-12-05. Interventions recorded: Blinatumomab.
Shares Blinatumomab, BeOne Medicines (formerly BeiGene), Amgen, T-cell engagers (bispecific) and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Blinatumomab, T-cell engagers (bispecific), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Amgen and the tag pipeline.